Tempus AI's stock faced a significant downturn as investors reacted to recent developments and market dynamics.
Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM) experienced a sharp decline of 6.59% in yesterday's trading session, closing at CA$76.50. This downturn comes amidst a backdrop of mixed news and shifting investor sentiment in the AI drug discovery sector.
Advertisement
Tempus AI, Inc. Class A Common Stock
TEM.US
TEM.US
Tempus AI, Inc. Class A Common Stock
WealthAwesomeMarket cap
$13.80B
52W high
$104.32
52W low
$40.77
1W change
-6.98%
Beta
3.72
Analyst Price Targets
Based on 12 analysts covering TEM · as of Sep 23, 2026
Wall Street analysts forecast TEM stock price to fall 10.4% over the next 12 months.
Consensus
Buy3.83 / 5.00
Avg. Target
C$68.56
-10.4% Upside
Previously C$68.18 on Sep 17, 2026
Current Price
C$76.50
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TEM's historical volatility
30-Day Vol
86.4%
Annualized
90-Day Vol
86.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$91.46
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$81.19 | C$60.26 – C$109.40 |
| 60 trading days | C$86.17 | C$56.52 – C$131.38 |
| 90 trading days | C$91.46 | C$54.56 – C$153.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Tempus AI navigates a challenging market environment, particularly in light of recent sell-offs by major investment firms.
6.59% Decline
Tempus AI's stock fell sharply, reflecting broader uncertainties in the AI and biotechnology markets.
Bull case
Tempus AI continues to innovate with its FDA-cleared AI products, which could drive future growth in healthcare as demand for AI-driven solutions rises.
Bear case
The significant reduction in holdings by prominent investment firms, such as Ark Invest, raises concerns about investor confidence and market sentiment surrounding Tempus AI's future prospects.
Advertisement
Market Reaction to Recent Developments
Tempus AI's stock plummeted yesterday following a series of mixed signals from the market. Despite receiving FDA clearance for its ECG-MR AI product, designed to identify undiagnosed mitral regurgitation, investor sentiment remained shaky. The broader AI drug discovery market is projected to grow significantly, but varying forecasts and the competitive landscape have left investors uncertain about Tempus AI's positioning.
Impact of Institutional Selling
The decline was exacerbated by Ark Invest's decision to cut its position in Tempus AI by approximately $7.7 million. This move by a prominent investment firm signals a lack of confidence in the stock's near-term prospects, prompting other investors to reassess their holdings. Such institutional selling can create a ripple effect, further driving down stock prices and affecting overall market sentiment.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
